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Abstract: <jats:italic>Purpose</jats:italic>. The aim of this retrospective study was to assess the
haemodynamic adverse effects of clonidine and dexmedetomidine in critically ill patients after cardiac
surgery. <jats:italic>Methods</jats:italic>. 2769 patients were screened during the 30-month study
period. Heart rate (HR), mean arterial pressure (MAP), and norepinephrine requirements were as-
sessed 3-hourly during the first 12 hours of the continuous drug infusion. Results are given as median
(interquartile range) or numbers (percentages). <jats:italic>Results</jats:italic>. Patients receiving
clonidine (<jats:italic>n</jats:italic> = 193) were younger (66 (57–73) vs 70 (63–77) years, <mml:math
xmlns:mml=”http://www.w3.org/1998/Math/MathML” id=”M1”><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.003</mml:mn></mml:mrow></mml:math>)
and had a lower SAPS II (35 (27–48) vs 41 (31–54), <mml:math xmlns:mml=”http://www.w3.org/1998/Math/MathML”
id=”M2”><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.008</mml:mn></mml:mrow></mml:math>)
compared with patients receiving dexmedetomidine (<jats:italic>n</jats:italic> = 141). At the start of
the drug infusion, HR (90 (75–100) vs 90 (80–105) bpm, <mml:math xmlns:mml=”http://www.w3.org/1998/Math/MathML”
id=”M3”><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.028</mml:mn></mml:mrow></mml:math>),
MAP (70 (65–80) vs 70 (65–75) mmHg, <mml:math xmlns:mml=”http://www.w3.org/1998/Math/MathML”
id=”M4”><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.093</mml:mn></mml:mrow></mml:math>),
and norepinephrine (0.05 (0.00–0.11) vs 0.12 (0.03–0.19) mcg/kg/min, <mml:math xmlns:mml=”http://www.w3.org/1998/Math/MathML”
id=”M5”><mml:mrow><mml:mi>p</mml:mi><mml:mo>lt;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math>)
were recorded in patients with clonidine and dexmedetomidine. Bradycardia (HR lt; 60 bpm) developed in
7.8% with clonidine and 5.7% with dexmedetomidine (<mml:math xmlns:mml=”http://www.w3.org/1998/Math/MathML”
id=”M6”><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.51</mml:mn></mml:mrow></mml:math>).
Between baseline and 12 hours, norepinephrine remained stable in the clonidine group (0.00 (−0.04–
0.02) mcg/kg/min) and decreased in the dexmedetomidine group (−0.03 (−0.10–0.02) mcg/kg/min,
<mml:math xmlns:mml=”http://www.w3.org/1998/Math/MathML” id=”M7”><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.007</mml:mn></mml:mrow></mml:math>).
<jats:italic>Conclusions</jats:italic>. Dexmedetomidine and the low-cost drug clonidine can both be
used safely in selected patients after cardiac surgery.
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Purpose. +e aim of this retrospective study was to assess the haemodynamic adverse effects of clonidine and dexmedetomidine in
critically ill patients after cardiac surgery. Methods. 2769 patients were screened during the 30-month study period. Heart rate
(HR), mean arterial pressure (MAP), and norepinephrine requirements were assessed 3-hourly during the first 12 hours of the
continuous drug infusion. Results are given as median (interquartile range) or numbers (percentages). Results. Patients receiving
clonidine (n� 193) were younger (66 (57–73) vs 70 (63–77) years, p � 0.003) and had a lower SAPS II (35 (27–48) vs 41 (31–54),
p � 0.008) compared with patients receiving dexmedetomidine (n� 141). At the start of the drug infusion, HR (90 (75–100) vs 90
(80–105) bpm, p � 0.028), MAP (70 (65–80) vs 70 (65–75) mmHg, p � 0.093), and norepinephrine (0.05 (0.00–0.11) vs 0.12
(0.03–0.19)mcg/kg/min, p< 0.001) were recorded in patients with clonidine and dexmedetomidine. Bradycardia (HR< 60 bpm)
developed in 7.8% with clonidine and 5.7% with dexmedetomidine (p � 0.51). Between baseline and 12 hours, norepinephrine
remained stable in the clonidine group (0.00 (−0.04–0.02)mcg/kg/min) and decreased in the dexmedetomidine group (−0.03
(−0.10–0.02)mcg/kg/min, p � 0.007). Conclusions. Dexmedetomidine and the low-cost drug clonidine can both be used safely in
selected patients after cardiac surgery.
1. Introduction
Maintaining an optimal level of comfort and safety for
critically ill patients is a universal goal in postoperative care
[1, 2]. +is can be achieved with the use of alpha-2 adrenergic
agents, in particular, clonidine and dexmedetomidine, which
induce dose-dependent sedation, analgesia, and anxiolysis
[3, 4]. Clonidine has traditionally been used in our institution
for sedation in the perioperative setting and in critically ill
patients after cardiac surgery [5–9]. Particular benefits of this
sedative are its low acquisition costs. Adverse effects of clo-
nidine are hypotension and bradycardia [10], which might
limit its use in haemodynamic unstable patients.
In 2013, dexmedetomidine was introduced into the Swiss
market. +e number of reports describing the benefits of
dexmedetomidine is growing continuously since then:
dexmedetomidine reduced the lengths of mechanical ven-
tilation and hospital stay, and it lowered the overall costs
compared with that of propofol [11–13]. +e perioperative
use of dexmedetomidine was associated with a decreased
incidence of postoperative complications, delirium, and
mortality up to one year after cardiac surgery [14]. However,
dexmedetomidine treatment is expensive and might not be
universally available.
To date, there is a shortage of studies comparing dex-
medetomidine and clonidine in the intensive care unit (ICU)
setting. +e only direct comparison between the two alpha-2
agonists available is limited by the low number of included
patients (n� 35 per group) [15].
2. Materials and Methods
2.1. Objectives. +e aim of this study was to assess the
haemodynamic adverse effects of the alpha-2 agonists clo-
nidine and dexmedetomidine in critically ill patients after
cardiac surgery.
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2.2. Design. +e study is a retrospective observational study.
+e study protocol was approved by the ethics council of the
Canton of Zurich, Switzerland (BASEC-Nr. PB_2016-
00333). Patients’ general consent was required for the
screening of their charts and the retrospective analysis of
their data.
2.3. Setting. +e study was performed in the cardiosurgical
ICU at the University Hospital Zurich, Switzerland. +e
treatment principles of patients hospitalized in this partic-
ular ICU have been summarized [16, 17]. In our practice,
patients generally arrive from the operation room under
propofol sedation. Alpha-2 agonists are second-line agents
when prolonged sedation becomes necessary. In our clinical
practice, clonidine is used in haemodynamically stable pa-
tients with norepinephrine requirements <0.1mcg/kg/min,
while dexmedetomidine is used in patients with a norepi-
nephrine requirement <0.3mcg/kg/min. +e patients re-
quiring higher norepinephrine support are usually sedated
with midazolam. However, no strict sedation guidelines
were applied during the study period, and the choice of
sedative was at the discretion of the ICU consultant on call.
2.4. Data Collection. Demographic and baseline character-
istics including the Simplified Acute Physiology Score
(SAPS) II were collected for both groups. Higher SAPS
values indicate more severe illness and a higher predicted
mortality [18]. Medical information and laboratory data
were extracted from the electronic patient information
system. Medication and haemodynamic variables were
collected from the handwritten patients’ charts.
2.5. Population. All patients admitted to our cardiovascular
ICU during an 18-month-period were screened for treat-
ment with either clonidine (Catapresan®) and/or dexme-
detomidine (Dexdor®). Study inclusion criteria for patients
were treatment with either clonidine or dexmedetomidine.
+e exclusion criteria were absence of consent for screening,
treatment with both clonidine and dexmedetomidine during
the same ICU stay, only drug bolus administration in ab-
sence of a continuous drug infusion, absence of cardiac
surgery, use of either extracorporeal life support, or ven-
tricular assist devices. Patients were included in the analysis
only once. +ose receiving both clonidine and dexmede-
tomidine during the same ICU stay were not considered for
this comparison.
2.6. Variables. Heart rate, mean arterial pressure, and
norepinephrine requirements were recorded 3-hourly. +e
observation period started with the beginning of the alpha-2
agonist infusion and ended 12-hours later. Bradycardia was
defined as a decrease of the heart rate below 60 beats per
minute.
2.7. Study Size. +e study size was defined by the 30-month
screening period (convenience sample).
2.8. Statistics. Median (interquartile range) and numbers
(percentages) were calculated for the overall sample and
subgroups. Missing values were replaced by the last recorded
value (carrying forward). Comparisons were made with the
use of the Mann–Whitney U test, Fisher’s exact test, or the
chi-squared test, as appropriate. +e null hypothesis was
rejected with a two-sided p value< 0.05. All analyses were
performed with the use of SPSS 24 for Windows 10.
3. Results
During the 30-month study period, 2769 patients were
admitted to the cardiosurgical ICU. A summary of included
and excluded patients is given in Figure 1. Eventually, this
study compared 193 patients sedated with clonidine and 141
patients sedated with dexmedetomidine. Patient charac-
teristics are displayed in Table 1.
All patients underwent cardiac surgery, which included
valve surgery in 179 (54%), coronary artery bypass surgery in
137 (41%), aortic dissection surgery in 35 (10.5%), aortic
aneurysm surgery in 50 (15%), other major vascular surgery
in 25 (7.5%), myocardial resection in 5 (1.5%), implantable
cardioverter defibrillator implantation in 12 (3.6%), and
heart transplantation in 9 (2.7%) patients. Several patients
received combinations of the above-listed interventions.
Cardiopulmonary bypass was required in 251 (75%) of the
operations without significant difference between the two
patient groups (p � 0.31). +e postoperative left ventricular
ejection fraction in both groups was 55 (45–60)%; p � 0.16.
+e average initial dose of clonidine was 0.38
(0.29–0.50)mcg/kg/h. +e average initial dexmedetomidine
dose was 0.80 (0.61–1.12)mcg/kg/h. Both drugs were started
on ICU day 2 (1–3); p � 0.18. Patients were treated with
clonidine for a total duration of 16 (11–50) hours. In the
dexmedetomidine group, patients received the drug infusion
for a total duration of 31 (13–68) hours. Study drug doses
over time are displayed in Figure 2.
Haemodynamic variables, laboratory values, and ICU
management at the start of clonidine or dexmedetomidine
treatment are shown in Table 2. As shown in Figure 3(a), the
median arterial pressure remained stable in both groups
during the twelve-hour observation period. Heart rate de-
creased in both groups by −10 (−20–0) bpm (p � 0.33),
Figure 3(b). Bradycardia developed in 7.8% of the patients
treated with clonidine and 5.7% of patients treated with
dexmedetomidine (p � 0.52). At the beginning of the alpa-2
agonist infusion, norepinephrine requirements were higher
in patients receiving dexmedetomidine (0.05 (0.00–0.11) vs
0.12 (0.03–0.19)mcg/kg/min, p< 0.001). Between baseline
and the twelve-hour follow-up, the norepinephrine re-
quirements remained stable in the clonidine group (0.00
(−0.04–0.02)mcg/kg/min), whereas a decrease of norepi-
nephrine was seen in the dexmedetomidine group (−0.03
(−0.10–0.02)mcg/kg/min, p � 0.007) (Figure 3(c)). During
the 12-hour observation period, a transient increase in
norepinephrine was recorded in 95 (49%) patients treated
with clonidine and 60 (43%) patients treated with dexme-
detomidine (p � 0.27) by 0.04 (0.03–0.08) and 0.06
(0.03–0.12)mcg/kg/min (p � 0.014), respectively.
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4. Discussion
+is retrospective analysis demonstrates that both clonidine
and dexmedetomidine can be used safely for sedation of
patients after cardiac surgery hospitalized in the ICU.
4.1. Population. Patients receiving dexmedetomidine were
older and had a higher SAPS II score and a higher re-
quirement for norepinephrine at the start of the drug in-
fusion, indicating that these patients had a higher severity of
illness than the patients treated with clonidine. +is reflects
Population (n = 2769)
All patients admitted to the cardio
surgical ICU between January 2013 and 
June 2015 
No clonidine or dexmedetomidine 
(n = 1770)
Patients with clonidine and/or
dexmedetomidine (n = 999)
Exclusion criteria:
No consent for screening (n = 76)
Readmission (n = 17)
Only clonidine bolus (n = 424)
No cardiac surgery (n = 28)
ECMO (n = 23)
VAD (n = 16)
Dexmedetomidine group (n = 141)Clonidine group (n = 193)
Patients with clonidine and/or
dexmedetomidine after exclusion
criteria (n = 415)
Study patients (n = 334)
Patients receiving both clonidine and
dexmedetomidine during the same
ICU stay (n = 81)
Figure 1: Study population with inclusion and exclusion criteria. ECMO: extracorporeal membrane oxygenation; VAD: ventricular assist
device; ICU: intensive care unit.
Table 1: Patient characteristics.
Variable All (n� 334) Clonidine group (n� 193) Dexmedetomidine group (n� 141) p value
Age (years) 68 (58–75) 66 (57–73) 70 (63–77) 0.003
Male gender 256 (77%) 145 (75%) 111 (79%) 0.513
Weight (kg) 78 (68–90) 79 (69–91) 78 (68–88) 0.188
SAPS II (points) 37 (29–50) 35 (27–48) 41 (31–54) 0.008
ICU length of stay (days) 5 (2–8) 4 (2–7) 6 (3–8) 0.004
ICU mortality 12 (3.6%) 7 (3.6%) 5 (3.5%) 1.000
ICU: intensive care unit; SAPS: simplified acute physiology score.
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our clinical practice that clonidine is used in haemody-
namically more stable patients. +is translated in a longer
ICU length of stay in the dexmedetomidine group, while
mortality was low in both groups.
4.2. Clonidine. We used clonidine in a median dose of
0.4mcg/kg/h, while Srivastava et al. used a mean dosage of
1.4mcg/kg/h. Haemodynamic instability is one of the most
frequently mentioned side-effects of clonidine [10].
Srivastava et al. described the frequencies for bradycardia
(heart rate below 50 bpm) and hypotension (systolic blood
pressure below 80mmHg or diastolic blood pressure below
50mmHg) during clonidine infusion with 8.6% (3/35) and
31% (11/35), respectively [15]. In our ICU setting, the overall
risk of bradycardia was below ten percent and mean arterial
blood pressure remained stable due to adjustments of the
norepinephrine doses. Overall, norepinephrine require-
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Figure 2: Drug dosages during dexmedetomidine and clonidine infusion. +e clonidine and dexmedetomidine doses decreased by −0.14
(−0.35–0.00)mcg/kg/h and −0.12 (−0.69–0.21), respectively. Values indicate median± interquartile range. Solid line (──) indicates clo-
nidine patients; dashed line (- - -) indicates dexmedetomidine patients. Values represent median (interquartile range).
Table 2: Physiological, laboratory, and treatment variables at the start of clonidine or dexmedetomidine therapy.
Variable All (n� 334) Clonidine group (n� 193) Dexmedetomidine group (n� 141) p value
Hemodynamic parameters
(i) Heart rate (1/min) 90 (80–100) 90 (75–100) 90 (80–105) 0.028
(ii) Mean arterial pressure (mmHg) 70 (65–75) n� 333 70 (65–80) n� 192 70 (65–75) 0.093
(iii) Central venous pressure (mmHg) 10 (7–12) n� 322 9 (6–12) n� 185 10 (8–13) n� 137 0.025
(iv) Cardiac index (l/m [2]/min) 2.7 (2.5–3.3) n� 51 2.6 (2.4–3.0) n� 19 2.8 (2.6–3.5) n� 32 0.101
(v) SvO2 (%) 69 (63–75) n� 239 69 (64–75) n� 173 65 (59–75) n� 66 0.060
Laboratory values
(i) Haemoglobin (g/l) 91 (83–103) n� 331 94 (85–107) 88 (80–97) n� 138 0.002
(ii) White blood cell count (G/l) 11.5 (8.8–15.1) n� 331 11.8 (8.8–15.1) n� 191 11.1 (8.6–15.1) n� 140 0.498
(iii) C-reactive protein (mg/l) 62 (14–131) n� 326 53 (6–133) n� 185 69 (34–129) 0.100
(iv) Procalcitonin (mcg/l) 1.91 (0.52–6.25) n� 46 1.43 (0.31–4.10) n� 28 3.46 (1.10–17.07) n� 18 0.075
(v) Creatinine (mcmol/l) 99 (78–141) 94 (76–133) 110 (83–150) 0.005
(vi) Aspartate transaminase (U/l) 62 (39–119) n� 322 55 (35–107) n� 184 71 (44–133) n� 138 0.026
(vii) Alanine transaminase (U/l) 27 (17–58) n� 325 27 (16–58) n� 188 28 (17–63) n� 137 0.606
(viii) Creatine kinase (U/l) 474 (242–847) n� 329 484 (228–889) n� 188 468 (255–807) n� 141 0.919
(ix) Myoglobin (mcg/l) 371 (218–767) n� 325 378 (229–670) n� 186 368 (214–898) n� 139 0.640
(x) Troponin (mcg/l) 0.81 (0.35–1.69) n� 320 0.78 (0.30–1.54) n� 184 0.84 (0.43–1.97) n� 136 0.135
(xi) Arterial lactate (mmol/l) 1.5 (1.0–2.3) n� 330 1.4 (1.05–2.2) 1.5 (1.0–2.6) n� 137 0.650
(xii) Arterial base excess (mmol/l) −1.1 (−3.0–0.3) n� 330 −1.2 (−2.7–0.3) −1.0 (−3.3–0.4) n� 137 0.574
Treatments
Propofol n (%) 127 (38%) 70 (36%) 57 (40%) 0.494
Mechanical ventilation
(i) Invasive n (%) 235 (70%) 124 (64%) 111 (79%) 0.017
(ii) Noninvasive n (%) 7 (2.1 %) 5 (2.6%) 2 (1.4%)
Renal replacement therapy-n (%) 34 (10.2 %) 23 (12%) 11 (7.8%) 0.235
Norepinephrine n (%) 248 (74 %) 133 (69 %) 115 (82%) 0.011
Inotropes
(i) Milrinone n (%) 80 (24%) 35 (18%) 45 (32%) 0.004
(ii) Epinephrine n (%) 73 (22%) 33 (17%) 40 (28%) 0.016
SvO2: central venous oxygen saturation. Variables were collected at start of clonidine or dexmedetomidine treatment.
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Figure 3: Hemodynamic variables during dexmedetomidine and clonidine infusion. Solid line (──) indicates clonidine patients; dashed line
(- - -) indicates dexmedetomidine patients. Values represent median (interquartile range).
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+emajor advantages of clonidine are its low costs. A 24-
hour treatment of an average study patient (body weight
79 kg, clonidine dose 0.4mcg/kg/h) costs about 18 Euros.
Based on our findings, we can recommend clonidine for
sedation in ICU patients after cardiac surgery with nor-
epinephrine requirements up to 0.1mcg/kg/min at the be-
ginning of the clonidine infusion, provided the patients are
adequately monitored and managed.
4.3. Dexmedetomidine. In the dexmedetomidine group,
patients were treated with a median dose of 0.8mcg/kg/h,
while Srivastava et al. used amean dose of only 0.4mcg/kg/h.
In the Midex and Prodex studies, the median dose of
dexmedetomidine was 0.45 and 0.96mcg/kg/h, respectively
[19]. Hypotension (no definition provided) occurred in 21%
(51/247) in the Midex study and in 13% (32/246) in the
Prodex study [19]. Srivastava et al. described the frequencies
for bradycardia (heart rate below 50 bpm) and hypotension
(systolic blood pressure below 80mmHg or diastolic blood
pressure below 50mmHg) during dexmedetomidine infu-
sion with 11% (4/35) and 8.6% (3/35), respectively [15]. In
our study, mean arterial blood pressure in the dexmede-
tomidine group remained stable over time. Less than half of
the patients being treated with dexmedetomidine showed a
transient increase of norepinephrine, while the overall
norepinephrine need was decreasing during the observation
period. +is suggests that dexmedetomidine provides good
haemodynamic stability.
In the Midex and Prodex studies, the risk of bradycardia
(no definition provided) was 14.2% (35/247) and 13.0% (32/
246), respectively [19]. In our study, the incidence of bra-
dycardia was 5.7% in the dexmedetomidine group.
Up to now, merely one existing study directly compared
the two alpha-2 agonists in the ICU setting. Srivastava’s
findings concerning the haemodynamic stability conform to
our findings, namely, that dexmedetomidine showed a better
haemodynamic stability than clonidine. However, due to
distinctive drug dosages, it is not possible to make a proper
comparison between the two studies: While we used twice as
much dexmedetomidine, our clonidine infusion doses were
lower by a factor of three. Additionally, Srivastava’s study is
limited by the small study group of 70 patients [15]. Re-
cently, Morelli et al. investigated the effect of dexmedeto-
midine sedation on norepinephrine requirements in 38
septic shock patients in a crossover trial. Four hours after the
stop of propofol and the initiation of a dexmedetomidine
infusion of 0.7± 0.2mcg/kg/h, the norepinephrine dose
decreased from 0.69± 0.72mcg/kg/min to 0.30± 0.25 μ·g/
kg/min (p< 0.005). Back on propofol 8 hours after stopping
dexmedetomidine, norepinephrine increased again to
0.42± 0.36 μg/kg/min (p< 0.005) [20]. While the study
population was different and the norepinephrine doses at
baseline were much higher, the dexmedetomidine doses
administered and the trend of the norepinephrine changes
were similar, supporting in part the findings of the present
study.
+e costs for a 24-hour treatment of dexmedetomidine
for an average study patient (body weight 78 kg,
dexmedetomidine dose 0.8mcg/kg/h) are approximately 224
Euros. Hence, dexmedetomidine therapy is exceeding the
costs of clonidine by more than ten times. While clonidine is
a good choice for haemodynamically stable patients
(NA≤ 0.1mcg/kg/min), our study results suggest that dex-
medetomidine is a safe option for patients with a moderate
haemodynamic instability (norepinephrine> 0.1,
but≤ 0.2mcg/kg/min). For highly unstable patients (nor-
epinephrine> 0.2mcg/kg/min), a treatment with another
sedative (e.g., midazolam) may be considered.
Based on these data, prospective studies can be planned
for a direct comparison between the two alpha-2 agonists,
potentially also in patients with haemodynamic instability.
More data regarding antidelirogenic effects and impact on
length of mechanical ventilation or length of stay are needed
for clonidine or dexmedetomidine treatments. As treatment
with clonidine is inexpensive compared with dexmedeto-
midine, further research would be of economic interest for
hospital administrators and public health.
4.4. Limitations. Our study has some important limitations.
First, this study has a retrospective design, and the patients
were not randomly allocated to a patient group. As a result,
the two patient groups have different baseline characteris-
tics, making a direct head-to-head comparison of the two
drugs impossible. However, this study represents a real-life
experience giving information on clinical practice in our
institution.
Second, all study variables were assessed 3-hourly and
reflect more the overall trend than short-term fluctuations.
Hence, if the patients showed relevant changes between the
assessment times, we might have missed those. Clearly, not
every variable of the patient condition (e.g., altertness and
pain) and ICU interventions (e.g., fluid administration,
analgesics, and termination of propofol) that may affect
blood pressure and heart rate was collected and analysed in
this study. In addition, some patients in our ICU had
transient epicardial pacemakers with the possibility of
pacing for haemodynamic reasons. +is may have had an
impact on the incidence of bradycardia in our study.
Nevertheless, our results reflect haemodynamic changes in
critically ill patients after cardiac surgery treated with alpha-
2 agonists under every day conditions.
5. Conclusions
In patients treated with clonidine or dexmedetomidine, the
incidence of bradycardia was below 10% and not different
between groups.With clonidine, half of the patients required
a mild increase in norepinephrine, while the overall nor-
epinephrine use remained constant over 12 hours. With
dexmedetomidine, less than half of the patients required a
norepinephrine increase, while the overall norepinephrine
use decreased during the observation period. +is suggests
that both dexmedetomidine and the lower-cost drug clo-
nidine can be used safely for sedation in selected patients
after cardiac surgery.
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Abbreviations
HR: Heart rate
ICU: Intensive care unit
MAP: Mean arterial pressure
SAPS: Simplified acute physiology score.
Data Availability
+e data used to support this study are available from the
corresponding author upon request.
Additional Points
To date, there is a shortage of studies comparing the car-
diovascular safety of dexmedetomidine and clonidine in the
intensive care unit setting. +is retrospective study assesses
the hemodynamic adverse effects of clonidine and dexme-
detomidine in critically ill patients after cardiac surgery.
Between baseline and 12 hours, norepinephrine require-
ments remained stable in the clonidine group and decreased
in the dexmedetomidine group. Bradycardia (HR< 60 bpm)
developed in less than 10% of patients with no difference
between groups. Dexmedetomidine and the low-cost drug
clonidine can both be used safely in selected patients after
cardiac surgery.
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